Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estramustine, Docetaxel, and Bevacizumab in Hormone Refractory Prostate Cancer
NCT00016107Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2001
- Primary completion
- Feb 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoints: Time to objective progression up to 2 years, Response rates (PSA and objective) up to 2 years and 1 more. Started Jun 2001; status: completed.
02
Drugs
bevacizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00016107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016107.